PL2970123T3 - Sól omekamtywu mekarbilu i sposób otrzymywania soli - Google Patents

Sól omekamtywu mekarbilu i sposób otrzymywania soli

Info

Publication number
PL2970123T3
PL2970123T3 PL14720369T PL14720369T PL2970123T3 PL 2970123 T3 PL2970123 T3 PL 2970123T3 PL 14720369 T PL14720369 T PL 14720369T PL 14720369 T PL14720369 T PL 14720369T PL 2970123 T3 PL2970123 T3 PL 2970123T3
Authority
PL
Poland
Prior art keywords
salt
omecamtym
mecarbil
obtaining
obtaining salt
Prior art date
Application number
PL14720369T
Other languages
English (en)
Inventor
Sheng CUI
Henry Morrison
Karthik Nagapudi
Shawn Walker
Charles Bernard
Karl Bennett Hansen
Neil Fred Langille
Alan Martin Allgeier
Steven MENNEN
Jacqueline WOO
Bradley Paul Morgan
Alex Muci
Original Assignee
Amgen Inc.
Cytokinetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2970123(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc., Cytokinetics, Inc. filed Critical Amgen Inc.
Publication of PL2970123T3 publication Critical patent/PL2970123T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL14720369T 2013-03-14 2014-03-14 Sól omekamtywu mekarbilu i sposób otrzymywania soli PL2970123T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785763P 2013-03-14 2013-03-14
EP14720369.9A EP2970123B2 (en) 2013-03-14 2014-03-14 Crystalline dihydrochloride hydrate salt of omecamtiv mecarbil and process for its preparation
PCT/US2014/027146 WO2014152270A1 (en) 2013-03-14 2014-03-14 Salt of omecamtiv mecarbil and process for preparing salt

Publications (1)

Publication Number Publication Date
PL2970123T3 true PL2970123T3 (pl) 2020-03-31

Family

ID=50549466

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14719472T PL2968173T3 (pl) 2013-03-14 2014-03-14 Związki heterocykliczne i ich zastosowania
PL14720369T PL2970123T3 (pl) 2013-03-14 2014-03-14 Sól omekamtywu mekarbilu i sposób otrzymywania soli

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL14719472T PL2968173T3 (pl) 2013-03-14 2014-03-14 Związki heterocykliczne i ich zastosowania

Country Status (43)

Country Link
US (16) US9951015B2 (pl)
EP (3) EP2968173B1 (pl)
JP (5) JP6498658B2 (pl)
KR (2) KR102374159B1 (pl)
CN (3) CN108785265B (pl)
AP (1) AP2015008789A0 (pl)
AR (2) AR095542A1 (pl)
AU (2) AU2014240049C1 (pl)
BR (2) BR112015022857B1 (pl)
CA (2) CA3147180C (pl)
CL (1) CL2015002708A1 (pl)
CR (1) CR20150549A (pl)
CY (2) CY1122695T1 (pl)
DK (2) DK2970123T4 (pl)
EA (1) EA031185B1 (pl)
ES (2) ES2837038T3 (pl)
FI (1) FI2970123T4 (pl)
HK (1) HK1218080A1 (pl)
HR (2) HRP20201967T1 (pl)
HU (2) HUE046285T2 (pl)
IL (2) IL240788B (pl)
JO (1) JOP20140114B1 (pl)
LT (2) LT2970123T (pl)
MA (2) MA38399B2 (pl)
ME (1) ME03566B (pl)
MX (3) MX2015012429A (pl)
MY (2) MY204971A (pl)
NZ (1) NZ711225A (pl)
PE (1) PE20151786A1 (pl)
PH (2) PH12019500176B1 (pl)
PL (2) PL2968173T3 (pl)
PT (2) PT2968173T (pl)
RS (2) RS59536B1 (pl)
RU (1) RU2663663C2 (pl)
SA (1) SA515361088B1 (pl)
SG (2) SG11201507258PA (pl)
SI (2) SI2970123T2 (pl)
SM (2) SMT201900563T1 (pl)
TN (1) TN2015000380A1 (pl)
TW (1) TWI667026B (pl)
UA (1) UA117011C2 (pl)
UY (1) UY35449A (pl)
WO (2) WO2014152270A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0512193B8 (pt) 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
TWI829098B (zh) 2015-01-02 2024-01-11 美商梅拉洛伊卡公司 細菌組成物
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
US11040956B2 (en) 2017-06-30 2021-06-22 Amgen Inc. Synthesis of omecamtiv mecarbil
LT3645002T (lt) 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
HUE052049T2 (hu) 2018-07-09 2021-04-28 Fis Fabbrica Italiana Sintetici Spa Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására
US11608318B2 (en) * 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
JP2021534138A (ja) 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
JP2022524609A (ja) 2019-03-12 2022-05-09 アムジェン インコーポレイテッド 心臓トロポニン活性化因子の多形及び共結晶
EP3938042A1 (en) * 2019-03-12 2022-01-19 Amgen Inc. Polymorphs of a cardiac troponin activator
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053189A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220402874A1 (en) * 2019-10-09 2022-12-22 Dr. Reddy's Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
CA3168513A1 (en) * 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
JP7825954B2 (ja) * 2020-08-26 2026-03-09 アムジエン・インコーポレーテツド Ｍｃｌ－１阻害剤処方物
TW202233189A (zh) 2020-11-12 2022-09-01 美商安進公司 藉由投與奧美卡替莫卡必爾治療心臟衰竭之方法
WO2022177927A1 (en) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
TW202300479A (zh) 2021-03-10 2023-01-01 美商安進公司 奧美卡替莫卡必爾之合成
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
WO2026050494A1 (en) 2024-08-29 2026-03-05 Cytokinetics, Incorporated Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2788775B1 (fr) 1999-01-22 2001-04-13 Pf Medicament Nouvelles n-alcoyl-n-[1-(omega-(arylalcoyloxy)alcoyl] piperidin-4-yl]-4h-3,1-benzo(thia/oxa)zines-2-amines substituees, leur preparation et leur application en therapeutique
AU783685B2 (en) 1999-12-23 2005-11-24 Pfizer Products Inc. Hydrogel-driven drug dosage form
GB0124455D0 (en) * 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
CA2463682A1 (en) 2001-10-17 2003-04-24 Aventis Pharma Deutschland Gmbh Method of reducing type 2 diabetes in high risk patients
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
BRPI0512193B8 (pt) 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
WO2007054975A1 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
PE20070823A1 (es) 2005-11-15 2007-08-09 Glaxo Group Ltd Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona
ES2419007T3 (es) 2005-12-15 2013-08-19 Cytokinetics, Inc. Ciertas entidades químicas, composiciones y procedimientos
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
EP1962852B1 (en) * 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
US7639112B2 (en) 2007-04-25 2009-12-29 Sony Corporation Fuse device with integrated switch
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
TW201006816A (en) * 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
WO2010040110A1 (en) 2008-10-03 2010-04-08 Pericor Therapeutics, Inc. Methods and compositions for treatment of acute heart failure
US9253433B2 (en) 2012-11-27 2016-02-02 International Business Machines Corporation Method and apparatus for tagging media with identity of creator or scene
AU2014240049C1 (en) 2013-03-14 2019-03-07 Amgen Inc. Heterocyclic compounds and their uses
AU2014240104B2 (en) * 2013-03-14 2018-11-08 Amgen Inc. Heterocyclic compounds and their uses
CA2975260C (en) 2015-01-29 2024-05-21 Signal Pharmaceuticals Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
US10543215B2 (en) 2015-06-26 2020-01-28 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
US11040956B2 (en) 2017-06-30 2021-06-22 Amgen Inc. Synthesis of omecamtiv mecarbil
LT3645002T (lt) 2017-06-30 2025-02-10 Amgen Inc. Širdies nepakankamumo gydymo būdas širdies sarkomerų aktyvatoriais
HUE052049T2 (hu) 2018-07-09 2021-04-28 Fis Fabbrica Italiana Sintetici Spa Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására
US11608318B2 (en) 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
JP2021534138A (ja) 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
WO2021053189A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
US20220402874A1 (en) 2019-10-09 2022-12-22 Dr. Reddy's Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
EP4041710A1 (en) 2019-10-09 2022-08-17 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
CA3168513A1 (en) 2020-02-10 2021-08-19 Amgen Inc. Omecamtiv mecarbil tablet
TW202233189A (zh) 2020-11-12 2022-09-01 美商安進公司 藉由投與奧美卡替莫卡必爾治療心臟衰竭之方法
WO2022177927A1 (en) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
TW202300479A (zh) 2021-03-10 2023-01-01 美商安進公司 奧美卡替莫卡必爾之合成
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Also Published As

Publication number Publication date
MA44637B1 (fr) 2021-04-30
MX363347B (es) 2019-03-20
TW201524507A (zh) 2015-07-01
CN108785265A (zh) 2018-11-13
US11958809B2 (en) 2024-04-16
US9951015B2 (en) 2018-04-24
AP2015008789A0 (en) 2015-10-31
CN105209437B (zh) 2018-09-18
CR20150549A (es) 2016-01-04
RS61215B1 (sr) 2021-01-29
IL241089B (en) 2019-10-31
US10421726B2 (en) 2019-09-24
AR095542A1 (es) 2015-10-21
MX2015012429A (es) 2016-04-07
IL240788B (en) 2020-09-30
CA2902646C (en) 2022-08-16
US12583821B2 (en) 2026-03-24
FI2970123T4 (fi) 2026-03-20
EP2970123B2 (en) 2025-12-10
HK1218080A1 (zh) 2017-02-03
TWI667026B (zh) 2019-08-01
SG10201706656RA (en) 2017-09-28
PH12015501998A1 (en) 2016-01-11
RS59536B1 (sr) 2019-12-31
KR20150136063A (ko) 2015-12-04
LT2970123T (lt) 2019-11-11
AR129504A2 (es) 2024-09-04
UY35449A (es) 2014-09-30
JP2016513683A (ja) 2016-05-16
HK1218544A1 (en) 2017-02-24
PH12015501998B1 (en) 2016-01-11
CN105120844A (zh) 2015-12-02
MA38399A1 (fr) 2017-01-31
AU2014239995B2 (en) 2018-07-26
HRP20201967T1 (hr) 2021-03-05
LT2968173T (lt) 2021-03-25
JP2022023891A (ja) 2022-02-08
ES2837038T3 (es) 2021-06-29
WO2014152236A1 (en) 2014-09-25
US12275704B2 (en) 2025-04-15
JP2016519071A (ja) 2016-06-30
MX2021001231A (es) 2021-04-12
US12221417B2 (en) 2025-02-11
US20160016906A1 (en) 2016-01-21
SMT202000685T1 (it) 2021-01-05
EP2968173A1 (en) 2016-01-20
US9988354B2 (en) 2018-06-05
US20200079736A1 (en) 2020-03-12
CY1122695T1 (el) 2021-03-12
SI2970123T2 (sl) 2026-04-30
MX2015012414A (es) 2016-04-25
KR102474467B1 (ko) 2022-12-05
HUE052355T2 (hu) 2021-04-28
UA117011C2 (uk) 2018-06-11
BR112015022857B1 (pt) 2022-10-25
JOP20140114B1 (ar) 2021-08-17
NZ750950A (en) 2020-09-25
SMT201900563T1 (it) 2019-11-13
US20140309235A1 (en) 2014-10-16
BR112015023417A2 (pt) 2017-07-18
US20200331859A1 (en) 2020-10-22
AU2014239995A1 (en) 2015-09-10
US11384053B2 (en) 2022-07-12
KR102374159B1 (ko) 2022-03-15
SI2968173T1 (sl) 2021-04-30
NZ711225A (en) 2020-06-26
MA38399B2 (fr) 2020-12-31
SI2970123T1 (sl) 2019-12-31
US20240317687A1 (en) 2024-09-26
HRP20191728T1 (hr) 2019-12-13
PH12019500176B1 (en) 2023-08-11
SG11201507258PA (en) 2015-10-29
CA3147180A1 (en) 2014-09-25
IL241089A0 (en) 2015-11-30
AU2014240049C1 (en) 2019-03-07
TN2015000380A1 (en) 2017-01-03
CY1123633T1 (el) 2022-03-24
KR20220045014A (ko) 2022-04-12
BR112015022857A2 (pt) 2017-07-18
EP3821882A1 (en) 2021-05-19
MY204971A (en) 2024-09-25
SA515361088B1 (ar) 2018-07-22
CA2902436A1 (en) 2014-09-25
EP2970123A1 (en) 2016-01-20
JP2019059746A (ja) 2019-04-18
PT2968173T (pt) 2020-12-18
EP2970123B1 (en) 2019-08-14
EA201591728A1 (ru) 2016-01-29
EA031185B1 (ru) 2018-11-30
AU2014240049A1 (en) 2015-09-10
HK1218512A1 (zh) 2017-02-24
US20180273479A1 (en) 2018-09-27
US20250376444A1 (en) 2025-12-11
US20200399221A1 (en) 2020-12-24
RU2663663C2 (ru) 2018-08-08
ME03566B (me) 2020-07-20
JP6498658B2 (ja) 2019-04-10
CA3147180C (en) 2024-04-23
US11472773B2 (en) 2022-10-18
ES2750676T3 (es) 2020-03-26
ES2750676T5 (en) 2026-03-12
US11884630B2 (en) 2024-01-30
JP2020125307A (ja) 2020-08-20
IL240788A0 (en) 2015-10-29
PH12019500176A1 (en) 2020-11-04
JP6966590B2 (ja) 2021-11-17
US20220153700A1 (en) 2022-05-19
MY186048A (en) 2021-06-17
DK2968173T3 (da) 2020-12-21
RU2015143643A (ru) 2017-04-18
US20230044617A1 (en) 2023-02-09
CN108785265B (zh) 2024-10-08
WO2014152270A1 (en) 2014-09-25
EP2968173B1 (en) 2020-10-14
JP6689942B2 (ja) 2020-04-28
US20240101517A1 (en) 2024-03-28
HUE046285T2 (hu) 2020-02-28
US20200277261A1 (en) 2020-09-03
PL2968173T3 (pl) 2021-03-08
DK2970123T3 (da) 2019-10-21
HK1219484A1 (zh) 2017-04-07
PE20151786A1 (es) 2015-12-11
US20250243163A1 (en) 2025-07-31
PT2970123T (pt) 2019-10-28
JP7174132B2 (ja) 2022-11-17
CL2015002708A1 (es) 2016-03-11
MA44637A1 (fr) 2019-08-30
US20180312469A1 (en) 2018-11-01
US20240217933A1 (en) 2024-07-04
DK2970123T4 (da) 2026-01-26
BR112015023417B1 (pt) 2023-10-17
US20220298114A1 (en) 2022-09-22
CA2902646A1 (en) 2014-09-25
AU2014240049B2 (en) 2018-07-19
JP6783138B2 (ja) 2020-11-11
CN105209437A (zh) 2015-12-30

Similar Documents

Publication Publication Date Title
IL291446A (en) Anti-trop2 antibodies and methods for producing same
IL271569B (en) Vaporization device systems and methods
PL3427584T3 (pl) Sposób zwalczania rdzy
PL3804863T5 (pl) Sposób aplikacji i system aplikacji
IL246002A0 (en) Novel methods
IL245036B (en) Pesticidal compositions and related methods
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
LT2970123T (lt) Omekamtivo mekarbilo druska ir jos gamybos būdas
PL3686205T3 (pl) Roztwór elektrolitu i sposób wytwarzania soli siarczanowej
PL3008852T6 (pl) System i sposób szyfrowania
EP2981902C0 (en) Automatic configuration of alarm aggregations
LT3007726T (lt) Tautopatijos gydymo būdai
IL243728A0 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
DK3022361T4 (da) Rambuk og fremgangsmåde til anvendelse deraf
BR112015021083A2 (pt) método
BR112015029076A2 (pt) método
ES2664077T8 (es) Cuerpo unido y método de unión
ZA201600927B (en) Structural assembly and method of assembly thereof
PL2979058T3 (pl) Sposób określania uszkodzenia pojazdu
HUE051592T2 (hu) Kezelési módszer
PL2883461T3 (pl) Sposób wytwarzania aktywnej folistatyny
PL2878369T3 (pl) Sposób powlekania
FI20130090L (fi) Prosessijärjestelmä ja -menetelmä
ES1078754Y (es) Trampa capturadora de avispas en colmenas
FI20135408L (fi) Autentikointimenetelmä